Format

Send to

Choose Destination
PLoS One. 2011;6(12):e28951. doi: 10.1371/journal.pone.0028951. Epub 2011 Dec 16.

Autoantibody signature differentiates Wilms tumor patients from neuroblastoma patients.

Author information

1
Department of Human Genetics, Medical School, Saarland University, Homburg, Germany. jana.schmitt@uniklinikum-saarland.de

Abstract

Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.

PMID:
22194956
PMCID:
PMC3241697
DOI:
10.1371/journal.pone.0028951
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center